Filing Details

Accession Number:
0001415889-24-017799
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-21 14:57:00
Reporting Period:
2024-06-18
Accepted Time:
2024-06-21 14:57:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1768446 Eliem Therapeutics Inc. ELYM Pharmaceutical Preparations (2834) 832273741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1969365 Emily Pimblett C/O Eliem Therapeutics, Inc.
Wilmington DE 19808
Chief Accounting Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-06-18 5,000 $0.00 5,000 No 4 M Direct
Common Stock Disposition 2024-06-20 1,245 $7.21 3,755 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-06-18 5,000 $0.00 5,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,000 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
  2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
  3. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  4. The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.